The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2026 | CAR-PRISM: cilta-cel in high-risk smoldering multiple myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses results from the Phase II CAR-PRISM study (NCT05767359) evaluating ciltacabtagene autoleucel (cilta-cel) in high-risk smoldering multiple myeloma. She highlights early findings showing sustained measurable residual disease (MRD)-negative responses across all treated patients and explores the potential of one-time immunotherapy approaches to achieve long-term disease control. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We were very excited to present CAR-PRISM this year. This was truly a passion, an idea that, you know, some people said was scary and crazy, but with patients who are excited and willing to do that, with the FDA approval, with, you know, pharmaceutical help, we were able to complete a 20-patient trial of cilta-cel without any induction, without any bridging. This is purely T-cells taken from the patients, engineered and given back to them...
We were very excited to present CAR-PRISM this year. This was truly a passion, an idea that, you know, some people said was scary and crazy, but with patients who are excited and willing to do that, with the FDA approval, with, you know, pharmaceutical help, we were able to complete a 20-patient trial of cilta-cel without any induction, without any bridging. This is purely T-cells taken from the patients, engineered and given back to them. And it’s their own immune cells that kill all the cancer cells. And the best data that I’ve seen so far is all of the patients, 20 patients, 100% MRD, negative disease, not 10 to the fifth, 10 to the sixth, and sustained. We have not seen that in any other trial where the survival curves are completely flat. It’s still early, and it’s still a very small number of patients, but we have about a two and a half years follow-up for the first few patients, and we’re hoping to continue follow-up. If the definition of cure is five years sustained MRD negative without being on therapy, we’re starting to see that with the first few patients coming along now in their third year. We’re very excited about that. Again, cilta-cel and CAR-T is not for everyone, but this was a proof of concept that indeed we can use one and done immunotherapy that will eradicate the cells. And so far, we haven’t seen any progression in those cases.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
